Navigation Links
Defectors take the car, cooperators go by bus
Date:2/3/2009

National economies are driven by the automobile, even during an economic downturn. Every day, hundreds of millions of people take their cars to visit remote places, to commute, and to reach the supermarket.

The total outlay for building roads amounts to trillions of dollars and millions of worker-hours. Miklos Szilagyi of the University of Arizona, Tucson suggests this is an apparent waste of resources, a serious producer of pollution, congestion, delays, and the fundamental reason for US dependence on foreign oil, but is mass transportation in large cities the best alternative. Should commuters take the bus rather than driving to work?

Writing in a forthcoming issue of the International Journal of the Internet and Enterprise Management, Szilagyi has used a computer simulation to help answer the transport dilemma of facing large cities.

The received wisdom suggests that the answer lies with public transportation. "If there were no cars but reliable trains and buses, everyone could get anywhere quickly and without traffic jams," says Szilagyi. His simulation greatly simplifies the issues, but works by considering each person to be cooperating if they use public transportation or defect if they selfishly choose to take their care. The decisions of all the individuals using the roads cooperatively or in defecting will accumulate over time to produce a collective order that will determine the success or failure of the transportation system.

If everyone defects, then there will be permanent gridlock. But, even if a few individuals choose the bus, this will not help, because the buses will also be gridlocked. Defectors and cooperators are both punished for the irresponsible behavior of the majority.

In contrast, if everyone uses the bus, the buses will be crowded although can move freely on otherwise empty streets. Everyone gets to their destination quickly but in less comfort and without the benefits of privacy, in-car audio, or a trunk for transporting cumbersome items.

If just a few individuals defect at this point, then they get the biggest reward, because they can move even faster, avoid the crowd in the bus, and have all the other advantages (and costs) of personal transport.

Szilagyi points out that the simulation reveals some of the characteristics of the well-known "game theory" game Chicken Dilemma. "The simulation shows that it is quite possible to achieve a situation when the majority of people prefer mass transportation," he says, "This can be done by running large buses frequently and on separate traffic lanes."

Ultimately, the simulation shows that if most people are happy to take the bus, and just a few people defect and drive by car, then there is a comfortable level of crowding on the buses, no gridlock and a few happy drivers with full trunks.


'/>"/>

Contact: Miklos Szilagyi
mns171717@yahoo.com
520-577-9275
Inderscience Publishers
Source:Eurekalert

Related biology news :

1. New southernpeas developed by ARS, cooperators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... Minn. , Feb. 7, 2017   MedNet ... supports the entire spectrum of clinical research, is pleased ... iMedNet , its innovative, highly flexible and award ... iMedNet customers. iMedNet is a proven ... provides Electronic Data Capture (EDC), but also delivers an ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... on Friday, February 24, 2017 a total of 10,672,750 common ... $0.13 per common share. Proceeds from the exercise of these ... InMed,s Treasury.   ... "We are grateful for this expression of confidence by ...
(Date:2/27/2017)... NEW YORK , February 27, 2017 ... up by Stock-Callers.com for evaluation today, and they are: ... ARWR), Pacific Biosciences of California Inc. (NASDAQ: PACB), and ... to an article on ETF Trends, market observers are ... Congress and administration could enact reforms to free cash ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences announced ... has been appointed as a Certified Service ... IsoFlux system will be used in Genetracer Biotech,s novel ... lung and colon cancer, with plans to move to ... is utilizing Fluxion,s IsoFlux System to isolate, recover, and ...
(Date:2/27/2017)... ... 27, 2017 , ... The Catalyst Midwest premix manufacturing facility has ... premix services and private label organic services. , The first organic product is Organic ... operating officer of Dynamite Marketing, which owns the facility. , Catalyst already has received ...
Breaking Biology Technology: